Lind Global Fund III LP Reports New 4.99% Stake in FibroBiologics, Inc. via Warrants and Common Stock

Lind Global Fund III LP, along with its general partner Lind Global Partners III LLC and managing member Jeff Easton, filed a Schedule 13G on April 9, 2026, reporting a new 4.99% stake in FibroBiologics, Inc. (FBLG). The reporting persons beneficially own 230,234 shares of common stock. This position is comprised of 157,956 shares of common stock and 540,536 warrants. However, the reported beneficial ownership is capped at 4.99% due to specific conversion limitations within the warrant agreements, which prevent the holder from exceeding this ownership threshold. The event triggering this filing occurred on April 2, 2026. The filing indicates that the shares were acquired for investment purposes and not with the intent to influence or change the control of the issuer. Jeff Easton maintains sole voting and dispositive power over the shares held by Lind Global Fund III LP. This filing marks a significant new holding for the group in the Houston-based biotechnology company.